Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Influenza Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The global influenza vaccine market reached a value of US$ 5.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 9.1 Billion by 2027, exhibiting a CAGR of 7.9% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Influenza is a contagious respiratory disorder that affects the throat, lungs, and nose. It leads to mild fever, chills, weakness, fatigue, muscle pain, headache, and soreness in the abdomen. It can be prevented using various specialized vaccines, such as Fluad Quadrivalent adjuvanted, Fluzone High-Dose Quadrivalent vaccine, and Flublok Quadrivalent recombinant flu shots. These vaccines provide protection against multiple types of influenza complications, such as pneumonia, bronchitis, and sinus and ear infections. Moreover, their effectiveness varies as per the route of administration, age, and health of patients. At present, the demand for influenza vaccines is increasing across the globe to prevent the spread of viral infections and minimize the high risk of developing severe flu complications.

 

 
 

www.imarcgroup.com

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about of this market, Request Sample

Influenza Vaccine Market Trends:

The increasing global geriatric population, which is more susceptible to immune deficiencies and infections, currently represents one of the key factors positively influencing the market. In addition, the rising prevalence of metabolic diseases, kidney diseases, and chronic neurological and lung disorders, such as bronchopulmonary dysplasia, asthma, and cystic fibrosis, increases the chances of developing influenza. This, in turn, is creating a positive outlook for the market. Apart from this, governments of several countries are continuously focusing on improving healthcare infrastructure and implementing various initiatives to monitor the administration, distribution, and supply of flu vaccines, which is strengthening the market growth. Furthermore, increasing investments by numerous public and private pharmaceutical companies in research and development (R&D) activities to develop therapeutically effective influenza vaccines are expected to propel the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global influenza vaccine market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on vaccine type, technology, age group and route of administration.

Breakup by Vaccine Type:

 

 
 

www.imarcgroup.com

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

  • Quadrivalent
  • Trivalent
     

The quadrivalent flu vaccine represents the most popular influenza vaccine type as it has the ability to immunize four different flu virus strains, including two influenza A viruses and two influenza B viruses.

Breakup by Technology:

  • Egg-based
  • Cell-based
     

The egg-based technology accounts for the majority of the market share due to its increasing use in formulating inactivated and live-attenuated vaccines.

Breakup by Age Group:

  • Pediatric
  • Adult
     

The pediatric age group represents the largest market segment as infants have weaker immune systems and are susceptible to higher risks of developing serious influenza complications.

Breakup by Route of Administration:

  • Injection
  • Nasal Spray
     

Based on the route of administration, the market has been bifurcated into injection and nasal spray.

Breakup by Region:

 

 
 

www.imarcgroup.com

To get more information on the regional analysis of this market, Request Sample

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

North America exhibits a clear dominance in the market due to the rising prevalence of influenza in the region. In addition, the easy availability of effective vaccines and technological advancements in vaccine manufacturing systems is favoring the market.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, CSL Limited, Daiichi Sankyo Company Limited, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gamma Vaccines Pty Ltd, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi and SINOVAC.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Billion
Segment Coverage Vaccine Type, Technology, Age Group, Route of Administration, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbott Laboratories, AstraZeneca plc, CSL Limited, Daiichi Sankyo Company Limited, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gamma Vaccines Pty Ltd, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi and SINOVAC
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

1   Preface
2   Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3   Executive Summary
4   Introduction

    4.1    Overview
    4.2    Key Industry Trends
5   Global Influenza Vaccine Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6   Market Breakup by Vaccine Type
    6.1    Quadrivalent
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Trivalent
        6.2.1 Market Trends
        6.2.2 Market Forecast
7   Market Breakup by Technology
    7.1    Egg-based
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Cell-based
        7.2.1 Market Trends
        7.2.2 Market Forecast
8   Market Breakup by Age Group
    8.1    Pediatric
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Adult
        8.2.1 Market Trends
        8.2.2 Market Forecast
9   Market Breakup by Route of Administration
    9.1    Injection
        9.1.1 Market Trends
        9.1.2 Market Forecast
    9.2    Nasal Spray
        9.2.1 Market Trends
        9.2.2 Market Forecast
10  Market Breakup by Region
    10.1    North America
        10.1.1 United States
           10.1.1.1 Market Trends
           10.1.1.2 Market Forecast
        10.1.2 Canada
           10.1.2.1 Market Trends
           10.1.2.2 Market Forecast
    10.2    Asia-Pacific
        10.2.1 China
           10.2.1.1 Market Trends
           10.2.1.2 Market Forecast
        10.2.2 Japan
           10.2.2.1 Market Trends
           10.2.2.2 Market Forecast
        10.2.3 India
           10.2.3.1 Market Trends
           10.2.3.2 Market Forecast
        10.2.4 South Korea
           10.2.4.1 Market Trends
           10.2.4.2 Market Forecast
        10.2.5 Australia
           10.2.5.1 Market Trends
           10.2.5.2 Market Forecast
        10.2.6 Indonesia
           10.2.6.1 Market Trends
           10.2.6.2 Market Forecast
        10.2.7 Others
           10.2.7.1 Market Trends
           10.2.7.2 Market Forecast
    10.3    Europe
        10.3.1 Germany
           10.3.1.1 Market Trends
           10.3.1.2 Market Forecast
        10.3.2 France
           10.3.2.1 Market Trends
           10.3.2.2 Market Forecast
        10.3.3 United Kingdom
           10.3.3.1 Market Trends
           10.3.3.2 Market Forecast
        10.3.4 Italy
           10.3.4.1 Market Trends
           10.3.4.2 Market Forecast
        10.3.5 Spain
           10.3.5.1 Market Trends
           10.3.5.2 Market Forecast
        10.3.6 Russia
           10.3.6.1 Market Trends
           10.3.6.2 Market Forecast
        10.3.7 Others
           10.3.7.1 Market Trends
           10.3.7.2 Market Forecast
    10.4    Latin America
        10.4.1 Brazil
           10.4.1.1 Market Trends
           10.4.1.2 Market Forecast
        10.4.2 Mexico
           10.4.2.1 Market Trends
           10.4.2.2 Market Forecast
        10.4.3 Others
           10.4.3.1 Market Trends
           10.4.3.2 Market Forecast
    10.5    Middle East and Africa
        10.5.1 Market Trends
        10.5.2 Market Breakup by Country
        10.5.3 Market Forecast
11  SWOT Analysis
    11.1    Overview
    11.2    Strengths
    11.3    Weaknesses
    11.4    Opportunities
    11.5    Threats
12  Value Chain Analysis
13  Porters Five Forces Analysis

    13.1    Overview
    13.2    Bargaining Power of Buyers
    13.3    Bargaining Power of Suppliers
    13.4    Degree of Competition
    13.5    Threat of New Entrants
    13.6    Threat of Substitutes
14  Price Analysis
15  Competitive Landscape

    15.1    Market Structure
    15.2    Key Players
    15.3    Profiles of Key Players
        15.3.1    Abbott Laboratories
           15.3.1.1 Company Overview
           15.3.1.2 Product Portfolio
           15.3.1.3 Financials
           15.3.1.4 SWOT Analysis
        15.3.2    AstraZeneca plc
           15.3.2.1 Company Overview
           15.3.2.2 Product Portfolio
           15.3.2.3 Financials
           15.3.2.4 SWOT Analysis
        15.3.3    CSL Limited
           15.3.3.1 Company Overview
           15.3.3.2 Product Portfolio
           15.3.3.3 Financials
           15.3.3.4 SWOT Analysis
        15.3.4    Daiichi Sankyo Company Limited
           15.3.4.1 Company Overview
           15.3.4.2 Product Portfolio
           15.3.4.3 Financials
           15.3.4.4 SWOT Analysis
        15.3.5    Emergent BioSolutions Inc.
           15.3.5.1 Company Overview
           15.3.5.2 Product Portfolio
           15.3.5.3 Financials
           15.3.5.4 SWOT Analysis
        15.3.6    F. Hoffmann-La Roche AG
           15.3.6.1 Company Overview
           15.3.6.2 Product Portfolio
           15.3.6.3 SWOT Analysis
        15.3.7    Gamma Vaccines Pty Ltd
           15.3.7.1 Company Overview
           15.3.7.2 Product Portfolio
        15.3.8    GlaxoSmithKline plc
           15.3.8.1 Company Overview
           15.3.8.2 Product Portfolio
           15.3.8.3 Financials
           15.3.8.4 SWOT Analysis
        15.3.9    Merck & Co. Inc.
           15.3.9.1 Company Overview
           15.3.9.2 Product Portfolio
           15.3.9.3 Financials
           15.3.9.4 SWOT Analysis
        15.3.10    Novartis AG
           15.3.10.1 Company Overview
           15.3.10.2 Product Portfolio
           15.3.10.3 Financials
           15.3.10.4 SWOT Analysis
        15.3.11    Pfizer Inc.
           15.3.11.1 Company Overview
           15.3.11.2 Product Portfolio
           15.3.11.3 Financials
           15.3.11.4 SWOT Analysis
        15.3.12    Sanofi
           15.3.12.1 Company Overview
           15.3.12.2 Product Portfolio
           15.3.12.3 Financials
           15.3.12.4 SWOT Analysis
        15.3.13    SINOVAC
           15.3.13.1 Company Overview
           15.3.13.2 Product Portfolio
           15.3.13.3 Financials

List of Figures

Figure 1: Global: Influenza Vaccine Market: Major Drivers and Challenges
Figure 2: Global: Influenza Vaccine Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Influenza Vaccine Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Influenza Vaccine Market: Breakup by Vaccine Type (in %), 2021
Figure 5: Global: Influenza Vaccine Market: Breakup by Technology (in %), 2021
Figure 6: Global: Influenza Vaccine Market: Breakup by Age Group (in %), 2021
Figure 7: Global: Influenza Vaccine Market: Breakup by Route of Administration (in %), 2021
Figure 8: Global: Influenza Vaccine Market: Breakup by Region (in %), 2021
Figure 9: Global: Influenza Vaccine (Quadrivalent) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Influenza Vaccine (Quadrivalent) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Influenza Vaccine (Trivalent) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Influenza Vaccine (Trivalent) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Influenza Vaccine (Egg-based) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Influenza Vaccine (Egg-based) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Influenza Vaccine (Cell-based) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Influenza Vaccine (Cell-based) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Influenza Vaccine (Pediatric) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Influenza Vaccine (Pediatric) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Influenza Vaccine (Adult) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Influenza Vaccine (Adult) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Influenza Vaccine (Injection) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Influenza Vaccine (Injection) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Influenza Vaccine (Nasal Spray) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Influenza Vaccine (Nasal Spray) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: North America: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: North America: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: United States: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: United States: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Canada: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Canada: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Asia-Pacific: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Asia-Pacific: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: China: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: China: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Japan: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Japan: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: India: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: India: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: South Korea: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: South Korea: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: Australia: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: Australia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: Indonesia: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: Indonesia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: Europe: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: Europe: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: Germany: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: Germany: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: France: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: France: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: United Kingdom: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: United Kingdom: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: Italy: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: Italy: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Spain: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: Spain: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Russia: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Russia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Latin America: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Latin America: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Brazil: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Brazil: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Mexico: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: Mexico: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Middle East and Africa: Influenza Vaccine Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Middle East and Africa: Influenza Vaccine Market: Breakup by Country (in %), 2021
Figure 73: Middle East and Africa: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 74: Global: Influenza Vaccine Industry: SWOT Analysis
Figure 75: Global: Influenza Vaccine Industry: Value Chain Analysis
Figure 76: Global: Influenza Vaccine Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Influenza Vaccine Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Influenza Vaccine Market Forecast: Breakup by Vaccine Type (in Million US$), 2022-2027
Table 3: Global: Influenza Vaccine Market Forecast: Breakup by Technology (in Million US$), 2022-2027
Table 4: Global: Influenza Vaccine Market Forecast: Breakup by Age Group (in Million US$), 2022-2027
Table 5: Global: Influenza Vaccine Market Forecast: Breakup by Route of Administration (in Million US$), 2022-2027
Table 6: Global: Influenza Vaccine Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 7: Global: Influenza Vaccine Market: Competitive Structure
Table 8: Global: Influenza Vaccine Market: Key Players


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Key Questions Answered in This Report

The global influenza vaccine market was valued at US$ 5.9 Billion in 2021.

We expect the global influenza vaccine market to exhibit a CAGR of 7.9% during 2022-2027.

The increasing geriatric population, along with the growing concerns among parents towards the well-being of their children, as they are at a high risk of complications from high fever, convulsions, and pneumonia, are primarily driving the global influenza vaccine market.

The increasing geriatric population, along with the growing concerns among parents towards the well-being of their children, as they are at a high risk of complications from high fever, convulsions, and pneumonia, are primarily driving the global influenza vaccine market.

Due to the sudden outbreak of the COVID-19 and the increasing death rate, there has been a rising demand for influenza vaccine to decrease the possibility of severe respiratory illness from the coronavirus infection and reduce the need for hospitalization.

Based on the vaccine type, the global influenza vaccine market can be segmented into quadrivalent and trivalent. Currently, quadrivalent holds the majority of the total market share.

Based on the technology, the global influenza vaccine market has been categorized into egg-based and cell-based, where egg-based currently exhibits a clear dominance in the market.

Based on the age group, the global influenza vaccine market can be divided into pediatric and adult. Currently, pediatric accounts for the largest market share.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global influenza vaccine market include Abbott Laboratories, AstraZeneca plc, CSL Limited, Daiichi Sankyo Company Limited, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gamma Vaccines Pty Ltd, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, and SINOVAC.

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4